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The extracellular matrix (ECM) is a complex meshwork of
cross-linked proteins providing both biophysical and bio-
chemical cues that are important regulators of cell prolifer-
ation, survival, differentiation, and migration. We present
here a proteomic strategy developed to characterize the in
vivo ECM composition of normal tissues and tumors using
enrichment of protein extracts for ECM components and
subsequent analysis by mass spectrometry. In parallel, we
have developed a bioinformatic approach to predict the in
silico “matrisome” defined as the ensemble of ECM pro-
teins and associated factors. We report the characteriza-
tion of the extracellular matrices of murine lung and colon,
each comprising more than 100 ECM proteins and each
presenting a characteristic signature. Moreover, using hu-
man tumor xenografts in mice, we show that both tumor
cells and stromal cells contribute to the production of the
tumor matrix and that tumors of differing metastatic poten-
tial differ in both the tumor- and the stroma-derived ECM
components. The strategy we describe and illustrate here
can be broadly applied and, to facilitate application of these
methods by others, we provide resources including labora-
tory protocols, inventories of ECM domains and proteins,
and instructions for bioinformatically deriving the human
and mouse matrisome. Molecular & Cellular Proteomics
11: 10.1074/mcp.M111.014647, 1–18, 2012.
The extracellular matrix (ECM)1 is a fundamental and impor-
tant component of metazoan organisms providing architectural
support and anchorage for the cells. The ECM consists of a
complexmeshwork of highly cross-linked proteins and exists as
interstitial formswithin organs and as specialized forms, such as
basement membranes underlying epithelia, vascular endothe-
lium, and surrounding certain other tissues and cell types (e.g.
neurons, muscles). Cells adhere to the ECM via transmembrane
receptors, among which integrins are the most prominent (1, 2).
These cell-matrix interactions result in the stimulation of various
signaling pathways controlling proliferation and survival, differ-
entiation, migration, etc. The composition of the ECM and the
repertoire of ECM receptors determine the responses of the
cells. The biophysical properties of the ECM (deformability or
stiffness) have also been shown to modulate these cellular
functions (3, 4). In addition to core ECM components (fibronec-
tins, collagens, laminins, proteoglycans, etc.), the ECM serves
as a reservoir for growth factors and cytokines and ECM-re-
modeling enzymes that collaborate with ECM proteins to signal
to the cells (5, 6). Hence, the ECM provides not only biophysical
cues but also biochemical cues that regulate cell behavior. In
addition to being important for normal development, alterations
of the ECM have been associated with various pathologies such
as fibrosis, skeletal diseases, and cancer (7–9) and it has been
emphasized recently that the ECM proteome needs better char-
acterization (10).
The role of the ECM in cancer is of particular interest.
Long-standing as well as recent data implicate tumor ECM as
a significant contributor to tumor progression. Indeed, the
ECM is a major component of the tumor microenvironment
(11, 12) and classical pathology has shown that excessive
deposition of ECM is a common feature of tumors with poor
prognosis. More recently, gene expression screens have re-
vealed that many genes encoding ECM components and
ECM receptors are dysregulated during tumor progression
(13–16). Finally, modifications of the extracellular matrix ar-
chitecture and biophysical properties have been shown to
influence tumor progression (6, 17, 18). Despite these clear
indications that tumor ECM and the interactions of cells with
it are very likely to play important roles in tumor progression,
we do not have a good picture of ECM composition, origins
and functions in tumors. One reason for this lies in the bio-
chemical properties of ECM proteins (large size, insolubility,
cross-linking, etc.) that have rendered very challenging at-
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tempts to characterize systematically the composition of the
ECM from tissues and tumors.
Thanks to the completion of the genomes of many species
and to previous studies (19–21), it is now clear that vertebrate
genomes contain hundreds of genes encoding ECM proteins.
Specific features of ECM proteins have emerged from these
studies, in particular their distinctive structures based on the
repetition of conserved domains (22, 23). During the last few
years, several attempts have been made at in silico predic-
tions of the complement of ECM proteins (24–26). Further-
more, recent studies have begun to characterize experimen-
tally the composition of the extracellular matrix of specific
model systems such as retinal and vascular basement mem-
branes (27–29), mammary gland (30, 31), and cartilage (32).
However, there remains a pressing need for a better definition
of the number and diversity of ECM proteins and even of what
should be included in that definition. Limitations arise also
from the lack of experimental reagents and approaches be-
cause of the biochemical intractability of ECM and the lack of
an adequate library of antibodies or other probes to charac-
terize ECM proteins in situ. Thus, deciphering the complexity
of the extracellular matrix in vivo represents an important
scientific challenge.
We describe here the development of proteomics-based
methods coupled with a bioinformatic definition of the “ma-
trisome” (ECM and ECM-associated proteins) to analyze the
protein composition of the tissue extracellular matrix. We
have successfully applied this strategy to characterize in de-
tail the extracellular matrices both of normal murine tissues
(lung and colon) and of melanoma tumors (nonmetastatic and
metastatic), which each comprise well over 100 proteins.
Moreover, we have applied this approach to understand the
origins of tumor ECM proteins and have been able to show,
using human into mouse xenograft models, that both tumor
cells and stromal cells contribute in characteristic ways to the
ECM of the tumor microenvironment. Furthermore, we show
that both tumor and stromal cells contribute to significant
changes in the extracellular matrices of tumors of differing
metastatic potential. The strategy we describe and illustrate
here can be broadly applied and we provide protocols and
inventories of ECM domains and proteins to facilitate appli-
cation of these methods by others.
EXPERIMENTAL PROCEDURES
Animal Models, Cell Culture and Human Tumor Cell Xenografts—
Normal tissues were from 8- to 12-week-old FVB mice. Lungs were
perfused by intracardiac injection with 3 ml of phosphate-buffered
saline to remove blood. Colon segments were rinsed with phosphate-
buffered saline to remove feces. A375 and MA2 human melanoma cell
lines (16) were grown in HyClone high-glucose Dulbecco’s modified
Eagle’s medium (Thermo Scientific) supplemented with 2 mM gluta-
mine and 10% fetal bovine serum (Invitrogen, Carlsbad, CA). Eight-
week-old NOD/SCID/IL2R null (Jackson Laboratory, West Grove,
PA) male mice were anesthetized using isoflurane (Abbott Laborato-
ries, North Chicago, IL) and 5.105 cells were injected subcutaneously
into the left flank of the mouse. Animals were sacrificed 5 weeks
post-injection and the tumors were dissected, flash frozen and kept at
80 °C.
Tissue Preparation and ECM Protein Enrichment—Sequential ex-
tractions of frozen samples of tissues or tumors were performed using
the CNMCS (Cytosol/Nucleus/Membrane/Cytoskeleton) Compart-
mental Protein Extraction kit (Cytomol, Union City, CA) according to
manufacturer’s instructions. In brief, frozen tissues (150–200 mg) or
tumors (200–j400 mg) were homogenized and extracted sequentially
to remove (1) cytosolic proteins (2), nuclear proteins (3), membrane
proteins (4), and cytoskeletal proteins leaving a final insoluble fraction
enriched for ECM proteins. Fractions were separated on SDS-poly-
acrylamide gradient gels, transferred to nitrocellulose membranes
and probed with antibodies to proteins characteristic of different
subcellular compartments (see Fig. 1A and Extended Experimen-
tal Procedures).
Mass Spectrometry—ECM-enriched fractions were solubilized in
urea, disulfide bonds reduced and alkylated, and proteins digested
with PNGaseF, Lys-C, and trypsin. Solutions that began cloudy upon
initial reconstitution were clear after overnight digestion. The resulting
peptides were separated by off-gel electrophoresis (OGE) according
to isoelectric point and by reversed-phase high-performance liquid
chromatography followed by tandem mass spectrometry (MS/MS) on
an LTQ Orbitrap mass spectrometer. Mass spectra were interpreted
with SpectrumMill and annotated using the matrisome bioinformatics
lists developed in this work. MS/MS spectra were searched against a
UniProt database containing either mouse only or both mouse
(53,448 entries) and human (78,369 entries) sequences; all sequences
(including isoforms and excluding fragments) were downloaded from
the UniProt web site on June 30, 2010. To each database a set of
common laboratory contaminant proteins (73 entries) was appended.
Peptides identified with a false discovery rate  2.5% were assem-
bled into identified proteins, and our in silico matrisome list was then
used to categorize all of the identified proteins as being ECM derived
or not. MS/MS spectra searches allowed for carbamidomethylation of
cysteines and possible carbamylation of N termini as fixed/mix mod-
ifications. Allowed variable modifications were oxidized methionine,
deamidation of asparagine, pyro-glutamic acid modification at N-ter-
minal glutamine, and hydroxylation of proline with a precursor MH
shift range of –18 to 97 Da. Hydroxyproline was only observed in the
proteins known to have it (collagens and proteins containing collagen
domains, emilins, etc.) and only within the expected GXPG sequence
motifs. supplemental Tables S7 and S8 containing the detailed pep-
tide spectral matches might have some examples not in the expected
motif when there is either a proline near the motif for which the
spectrum could have had insufficient fragmentation to confidently
localize the mass change to a particular residue, or a nearby methi-
onine in the peptide and the spectrum had insufficient fragmentation
to localize the mass change to oxidized Met or hydroxyproline. When
the motif nX[ST] occurs in a peptide in supplemental Tables
S7 and S8, this is likely to indicate a site where N-linked glycosylation
was removed by the PNGaseF treatment of the sample. Although a
lowercase n indicates a gene-encoded asparagine residue detected
in aspartic acid from, possible mechanisms of modification such as
acid-catalyzed deamidation during sample processing versus enzy-
matic conversion during deglycosylation cannot be explicitly distin-
guished. Our automated database searching based interpretation of
the MS/MS spectra did not attempt to detect any of the many known
examples of crosslinking previously observed in collagen family pro-
teins (33, 34) nor did our sample processing methods attempt to
enrich for or deplete crosslinked peptides from the samples. Conse-
quently, the spectra generated in this study may be a valuable re-
source to mine for sites and forms of collagen crosslinking. Additional
detailed information can be found in the Extended Experimental Pro-
cedures. The raw LC-MS/MS data associated with this manuscript
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Bioinformatic Definition of Extracellular Matrix Proteins—The hu-
man and mouse proteomes were each screened for proteins contain-
ing domains characteristic of ECM proteins, ECM-affiliated pro-
teins, ECM modifiers and secreted factors. Those lists were
subsequently screened to eliminate proteins that shared one or
more of the defining domains but were not ECM or ECM-associated
proteins based on other criteria. Detailed information can be found
in the Extended Experimental Procedures. We have also deployed
a webpage providing collection of resources (data files, sequence
files) and further annotations on the bioinformatic pipeline devel-
oped for this study http://web.mit.edu/hyneslab/matrisome/.
Immunohistochemistry—Tumor samples were formalin-fixed and
paraffin-embedded. Sections were dewaxed and rehydrated follow-
ing standard procedures. Antigen retrieval was performed by incu-
bating sections in boiling 10 mM sodium citrate buffer (pH6.0) for 20
min. Sections were then blocked with PBS containing 4% ovalbumin.
Incubation with rabbit anti-HAPLN1 antibody (Sigma) was performed
overnight at 4°C and secondary antibody incubation, 2 h at room
temperature. Secondary goat-anti-rabbit antibody conjugated with
Alexa-568 was from Invitrogen. Sections were counterstained with
DAPI (4,6-diamidino-2-phenylindole) to visualize nuclei.
RESULTS
ECM Protein Enrichment From Tissues—Analysis of the
protein composition of the extracellular matrix presents chal-
lenges due to the diversity, large size, insolubility and cross-
linking of these proteins. By contrast, most other cellular
components are soluble even at relatively low concentrations
of salt or detergents. Therefore, we took advantage of the
insolubility of ECM proteins to enrich for them while depleting
other cellular components. We used a subcellular fraction-
ation protocol to extract sequentially components from the
cytosol, the nucleus, the membrane and the cytoskeleton and
enrich for ECM proteins (see Extended Experimental
Procedures). Fig. 1A shows the sequential extraction of pro-
teins from the different cellular compartments, using diagnos-
tic marker proteins for each compartment. ECM proteins such
as fibronectin (as well as laminins and collagens, not shown)
were not extracted during these intermediate steps and were
found to be enriched in the final insoluble fraction.
Development of a Proteomics-based Strategy to Character-
ize the Composition of ECM In Vivo—To analyze the compo-
sition of the ECM-enriched fractions obtained after depletion
of other cellular components, we digested the proteins to
peptides and employed a proteomics pipeline shown in Fig.
1B using liquid chromatography combined with tandem mass
spectrometry (LC-MS/MS) to identify peptides and proteins
(see Extended Experimental Procedures). Analysis by LC-
MS/MS of ECM proteins enriched from murine lung and di-
gested to peptides confirmed a significant enrichment for
matrix proteins, with more than 75% of the total precursor ion
intensity (the sum of MS1 precursor ion peak areas for all
identified peptides) corresponding to proteins defined as
ECM (Fig. 2A, left panel). To help measure the success of our
enrichment strategy and focus downstream biological fol-
low-up we sought to categorize the identified proteins as
being ECM-derived or not. The categorization of each protein
identified by mass spectrometry was initially performed using
FIG. 1. Extracellular matrix enrichment protocol and proteomic
analysis. A, ECM protein enrichment from total tissue sample. The
extraction of intracellular components from [1] cytosolic, [2] nuclear,
[3] membrane and [4] cytoskeletal fractions was monitored by im-
munoblotting for GAPDH (cytosol), histones (nucleus), the transfer-
rin receptor (plasma membrane) and vimentin (cytoskeleton). The
remaining insoluble fraction was enriched for ECM proteins (as
shown in the fibronectin panel) and largely depleted for intracellular
components. B, Proteomics workflow (see Extended Experimental
Procedures).
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FIG. 2. Characterization of the ECM of murine lung. A, Characterization of the ECM-enriched fraction from lung by LC-MS/MS proteomics.
The pie charts display the results from one murine lung sample processed through the proteomics workflow. Proteins represented by at least
two peptides were included in the analysis. Left panel shows the peptide abundance by precursor-ion MS signal corresponding to different
protein categories. Middle panel: distribution in terms of numbers of peptides. Right panel: distribution in terms of numbers of proteins. The
“core matrisome” division comprises ECM glycoproteins, collagens and proteoglycans; the “matrisome-associated” protein division encom-
passes ECM-affiliated proteins, ECM regulators and Secreted factors (see discussion in text and Fig. 3). MS data are presented in
supplemental Table S1. B, Mass spectrometry results after peptide separation into 11 fractions by off-gel electrophoresis (OGE). The pie charts
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the Gene Ontology (GO) “Cellular Compartment” annotations.
However, this annotation showed several clear limitations. For
example, several cytosolic or cytoskeletal proteins involved in
cell-matrix adhesion are mis-annotated as being part of the
extracellular matrix (see supplemental Table S1); conversely,
some known ECM proteins (thrombospondin 1, von Will-
ebrand factor, agrin, etc.) are defined by vague terms such as
“external side of the plasma membrane” or “cell surface”
(supplemental Table S1). In addition more than 20 different
GO categories correspond to the extracellular matrix (extra-
cellular matrix, basal lamina, basement membrane, etc.) and
yet UniProt identifiers for some known ECM proteins are not
associated with any cellular compartments in the Gene On-
tology database. Finally, and of importance to the study of
human/mouse xenografts (see below), we noted conflicting
annotations between human and mouse proteins. In order to
interpret the mass spectrometric data we needed a better
definition of which proteins should be considered as part of
the ECM.
In Silico Definition of the Matrisome—Therefore, we devel-
oped a bioinformatic approach to predict within any genome
the ensemble of genes encoding what we define as the “ma-
trisome,” namely all those components constituting the extra-
cellular matrix (the “core matrisome”) and those components
associated with it (“matrisome-associated” proteins). One
hallmark of ECM proteins is their domain-based structure (23).
Exploiting this characteristic, we established a list of 55 diag-
nostic InterPro domains commonly found in ECM proteins
(type I, II and III fibronectin domains, type I thrombospondin
repeats, laminin G domain, etc.; Fig. 3A and supple-
mental Table S2A). This domain list was used to screen the
UniProt protein database. We know that some of the domains
used to select positively for ECM proteins are also found in
transmembrane receptors and proteins involved in cell adhe-
sion (growth factor receptors, integrins, etc) that do not be-
long to the ECM. These families of proteins also display a
subset of specific domains (e.g. tyrosine kinase and phospha-
tase domains) and transmembrane domains incompatible
with definition as “extracellular matrix” proteins. Therefore, a
second step comprised a negative selection using 20 do-
mains (supplemental Table S2B) and a transmembrane do-
main prediction (see Extended Experimental Procedures for
details). This analysis was performed in parallel for both the
mouse and human genomes and the respective murine and
human matrisome lists were compared based on orthology.
Manual curation of the matrisome lists also allowed us to add
a very few known ECM proteins that do not contain any
known domains; for example, dermatopontin and dentin sia-
lophosphoprotein (supplemental Table S3). Finally, knowl-
edge-based annotation of these gene lists allowed us to de-
fine subcategories within the core matrisome; namely, ECM
glycoproteins, collagens, and proteoglycans. The bioinfor-
matics workflow developed is presented in Fig. 3B and de-
fined sets of core matrisome proteins from both species are
listed in supplemental Table S3.
We also wished to characterize those proteins that are
known to be associated with the ECM, but are not included in
the core list of ECM proteins. To this end, we defined separate
lists of domains commonly found in 1) ECM-affiliated proteins
(proteins that share either some architectural similarities with
ECM proteins or that are known to be associated with ECM
proteins, or that repeatedly appeared in our proteomics
display the result of one murine lung sample processed through the proteomics workflow. Proteins represented by at least two peptides were
included in the analysis. Left panel shows the peptide abundance by precursor-ion MS signal corresponding to the different divisions of the
matrisome. Middle panel: distribution in terms of numbers of peptides. Right panel: distribution in terms of numbers of proteins. Note the
increase in number of matrisome and matrisome-associated proteins detected in each category and the larger increase in nonECM proteins;
that is, the increase in apparent “noise” relative to “signal” for ECM proteins. MS data are presented in supplemental Table S4A, sample 1. C,
Comparison of the number of core matrisome and matrisome-associated proteins detected before and after peptide separation by OGE. D,
Comparison of the number of peptides belonging to the core matrisome and matrisome-associated proteins before and after OGE.
TABLE I
Number of genes encoding the matrisome within the human and
mouse genomes. The core matrisome comprises 278 genes in the
human genome (274 in the mouse) and includes genes encoding ECM
glycoproteins, collagens, and proteoglycans. The subsequent assign-
ment to each category was based on presence of signature domains
(for example, the decorin/asporin/biglycan domain is a proteoglycan-
specific domain, whereas, the type 4 procollagen, C-terminal repeat is
a collagen-specific domain) and on prior knowledge and data from the
literature (see Extended Experimental Procedures)
The matrisome-associated set of genes includes: 1) genes encod-
ing ECM-affiliated proteins ie. proteins that share either some archi-
tectural or biochemical similarities with ECM proteins (ficolins, mu-
cins, etc.) or that are known to be associated with ECM proteins,
either from prior information or from our own results (semaphorins,
annexins, galectins, etc.), 2) ECM regulators, including ECM-remod-
eling enzymes such as transglutaminases, lysyl oxidases, matrix met-
alloproteinases, serpins etc. and their regulators and 3) genes encod-
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analyses of ECM-enriched fractions; see Tables I and
supplemental Table S2 and S4); 2) ECM regulators (ECM-
remodeling enzymes, crosslinkers, proteases, regulators etc.);
3) secreted factors, many of which are known to bind to ECM
and others that may (supplemental Table S2A). As for the core
matrisome list, we also defined lists of domains that excluded
FIG. 3. Bioinformatics pipeline used to define the in silico core matrisome. A, List of the 55 InterPro domains used to define the core
matrisome. This list was compiled based on prior knowledge, data from the literature and iterative query of UniProt as described in Extended
Experimental Procedures (see also supplemental Table S2A). B, Schematic representation of the bioinformatic pipeline (see text,
Extended Experimental Procedures and supplemental Fig. S1).
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mis-assigned proteins from these categories (supplemental
Table S2B). Using similar bioinformatic pipelines as for the
core matrisome, we defined three categories of “matrisome-
associated” proteins: ECM-affiliated proteins, ECM regula-
tors, and secreted factors (supplemental Fig. S1).
This bioinformatics approach allowed us to characterize
the in silico human and mouse matrisomes (supplemental
Table S3A and 3B respectively). The human core matrisome is
composed of 278 genes corresponding to somewhat more
than 1% of the proteome, the complete matrisome, with 1056
genes, accounting for 4% of the human proteome (Table I
and supplemental Table S3A). In addition to 43 known collagen
genes, we conclude that the human genome encodes 200 ECM
glycoproteins and 35 proteoglycans. As expected, the human
and murine genomes encode very similar collections of matri-
some proteins (Table I and supplemental Table S3B). In
addition to providing a comprehensive in silico atlas of ECM and
ECM-associated proteins, which includes all previously known
ECM proteins, we report here the identification of potential
novel ECM proteins that display architectures similar to ECM
proteins but that have not previously been reported to be part of
the ECM (highlighted in supplemental Table S3). These lists are
intended to evolve as the in vivo characterization progresses
and one might wish to add more proteins or domains to this
bioinformatic pipeline in the future.
Characterization of the Extracellular Matrix of Murine Lung—
The categorization of all the proteins identified by mass spec-
trometry in the ECM-enriched fraction, using our bioinformatic
definition, revealed the presence of 55 matrisome proteins out
of 184 proteins detected in the simple LC-MS/MS analysis (i.e.
without peptide separation by OGE, see below; see Fig. 2A and
supplemental Table S1A). The other 70% of proteins detected
represent insoluble intracellular components such as proteins
associated with the actin cytoskeleton or with intermediate fil-
aments plus a few transmembrane proteins (supple-
mental Table S1A). However these “contaminating” proteins
remain aminority fraction as they represent less than 25%of the
precursor-ion MS intensity (Fig. 2A, left panel). The addition of
an intermediate fractionation step by off-gel electrophoresis
(OGE, separation of the peptide mixture into 11 fractions ac-
cording to isoelectric point, see Extended Experimen-
tal Procedures), before submitting the peptides to LC-MS/MS,
increased by a factor of 4 the total number of peptides detected
(Fig. 2B middle panel and 2D), corresponding to sixfold more
total proteins detected with two or more peptides per protein
(Fig. 2B, right panel). However, this step led to only a threefold
increase in the number of matrisome proteins, indicating that
the analysis is approaching a plateau in the level of detection of
matrisome proteins. Interestingly, this additional step increased
by a factor of 15 the number of matrisome-associated proteins
detected in the sample. Moreover, it was only after peptide
separation by OGE that we detected the presence of growth
factors in our samples (Fig. 2C and supplemental Table S4A;
see Discussion).
To test the reproducibility of the pipeline, we processed a
second sample and found a large overlap of the matrisome
proteins detected in the two samples, which showed 80%
identity when considering proteins identified by two peptides
(Fig. 4A and supplemental Table S4A). The overlap is partic-
ularly evident for the most abundant core matrisome proteins
belonging to the collagen and proteoglycan categories (Fig.
4A, right panel). Therefore, to define the extracellular matrix
composition of a tissue, we combined the data from two
independent samples including only those proteins recovered
in both samples represented by at least two peptides in at
least one of the samples. By this definition, the extracellular
matrix of murine lung comprises 143 total matrisome proteins:
92 core matrisome proteins, and 51 matrisome-associated
proteins (supplemental Table S4B).
Tissue Specificity of Extracellular Matrix Composition—Us-
ing the same pipeline and criteria, we characterized the mu-
rine colon extracellular matrix (supplemental Table S4D). Rep-
licate ECM-enriched colon samples overlapped by 85% (Fig.
4B, left panel and supplemental Table S4C). As for the ECM-
enriched lung fractions, reproducibility is particularly evident
for the most abundant core matrisome proteins belonging to
the collagen and proteoglycan categories (Fig. 4B, right
panel).
Comparison of the lung and colon extracellular matrices
allowed definition for each of these tissues of a “matrisome
signature”; i.e. the subset of matrisome proteins displaying
tissue-specific expression (Table II). A core set of 84 matri-
some proteins were consistently found in both lung and colon
matrisomes (see Fig. 4C). The vast majority of collagens,
proteoglycans and components of the basement membrane
(laminins a-chains 2, 3, 4, 5, b-chains 2 and 3 and chain c1,
nidogen, perlecan) were found in both tissues. In addition,
these categories of shared proteins are abundant, as indi-
cated by the peptide precursor ion abundance and number of
peptides detected by MS (Table II).
In addition to this common set of 84 proteins, 59 matrisome
proteins were detected exclusively in the lung and 22 matri-
some proteins were detected only in the colon. These differ-
entially expressed proteins belong mainly to the ECM glyco-
protein, ECM-affiliated, ECM regulators and secreted factor
categories (Fig. 4C). Some of these tissue-specific proteins
conform in obvious ways with the organ’s physiology. For
example, thrombospondin 1 (Thbs1) is expressed in the lung
but not detected in the colon. This protein was found to be
differentially expressed in total ECM preparations of lung
versus colon by LC-MS/MS without peptide separation by
OGE, indicating that it is an abundant component of the lung
ECM. In addition, thrombospondin 1 has previously been
shown to play a role in lung physiology (35). Conversely,
mucin 2 (Muc2), a protein known to be secreted by the goblet
cells of the colon is specifically found in the ECM of colon and
not in the ECM of lung (36). Similarly, galectin 4 (Lgals4) has
been shown to be expressed exclusively in the digestive tract
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and is found only in the ECM of colon (37). This same strategy
can be applied to various other tissues to characterize bio-
chemically the complete tissue matrices in much greater de-
tail than has been possible heretofore.
Experimental Coverage of the In Silico Matrisome—Com-
parison of the proteins detected in vivo with the predicted in
silicomatrisome shows that33% of the 274 core matrisome
proteins and 11% of the 1098 total murine matrisome proteins
(core plus associated) characterized in silico were detected at
the protein level in the lung (Fig. 4D). Considering both lung
and colon together, we detected 8 of the 36 predicted pro-
teoglycans encoded by the murine genome (22%). The num-
ber of collagens found to be expressed in either the lung or
the colon reached 70% of the total predicted in silico (Fig. 4D).
We suspect that the other proteoglycans and collagens not
detected will be found in other tissue types (see Discussion).
Similar conclusions can be drawn for the ECM glycoproteins
of the core matrisome. The representation of the predicted
ECM-associated proteins in our experimental samples is sig-
nificantly lower; we detect fewer than 15% of the predicted
matrisome-associated proteins (Fig. 4D). Low abundance and
tissue-specificity of many of these proteins, no doubt, con-
tribute to the lower coverage of these sectors of the in silico
lists. However, it is also possible that greater solubility might
account for the fact that they are not detected in our samples
(see Discussion).
The Composition of the Tumor ECM Changes With the
Tumor’s Metastatic Potential—Having developed this strat-
egy, we wished to apply it to begin to tackle several questions
about the tumor microenvironment. As discussed in the Intro-
duction, changes in the ECM of tumors are of considerable
interest. One challenging question is to determine whether the
composition of tumor extracellular matrix differs in tumors
with different metastatic ability. Accordingly, we grew subcu-
taneous tumors by injection into NOD/SCID/IL2R mice of
A375 human melanoma cells (poorly metastatic) or their highly
metastatic derivatives MA2 (16). The tumors were dissected 5
FIG. 4. Reproducibility of the proteomic analysis. A, Two lung
samples were analyzed through the proteomics pipeline and inter-
sample variability was assessed. Venn diagram shows reproducibility in
terms of number of matrisome proteins identified by two peptides in
each of two independent samples. Bar chart represents the matrisome
proteins detected in the two independent samples (see supple-
mental Table S4A). B, Two colon samples were analyzed through the
proteomics pipeline and intersample variability was assessed. Venn
diagram shows reproducibility in terms of number of matrisome pro-
teins identified by two peptides in each of two independent samples.
Bar chart represents the matrisome proteins detected in two inde-
pendent samples (see supplemental Table S4C). C, Bar chart repre-
sents the overlap and tissue specificity for the lung and colon within
each category of matrisome proteins. Venn diagram shows the num-
ber of matrisome proteins overlapping between the lung and colon
and the number of tissue-specific matrisome proteins. Here, proteins
are included only if they are found in both samples from a given tissue
and represented by two peptides in at least one of them. D, Left
panel: Comparison of the in vivo matrices of lung and colon core
matrisome sets with the predicted in silico core matrisome. Right
panel: Comparison of the in vivo lung and colon matrisome-associ-
ated sets of proteins with the predicted in silico matrisome-associ-
ated set of genes.
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TABLE II
Tissue specificity of the extracellular matrix. Color code represents the number of peptides and total peptide precursor ion abundance of each
protein in the two independent samples used to define each of the lung and colon matrices. Values used to generate the table were extracted
from columns F (number of peptides) and I (peptide abundance) of supplemental Table S4B (lung) and supplemental Table S4D (colon). Dash
(—) indicates that the protein was not found in either sample from a given tissue. Proteins included in this table were found in two independent
samples with at least two peptides in one of the two samples. Uniprot accession numbers are given in supplemental Table S4
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weeks later, and the tumor ECM was enriched using the
protocols outlined above. As before, we define the tumor
ECM as the ensemble of ECM proteins and ECM-associated
proteins found in two independent samples (supple-
mental Table S5). The analysis of the composition of matrix
from A375 or MA2 tumors revealed that the majority of the
matrisome proteins detected were expressed by both tumor
types and in comparable proportions (fibronectin, LTBP3 and
4, periostin, etc.) (Table III). In addition, this study also re-
vealed the differential expression of matrisome proteins.
Basement membranes are specialized forms of extracellular
matrix of defined composition that are found at the interfaces
between epithelia and connective tissues and underlying the
endothelial cells of the blood vessel wall. In this comparative
study, most of the basement membrane components (type IV
and XV collagens, laminins, HSPG2 or perlecan, nidogen 2)
were found to be expressed in the same proportions by the
two tumor types although we could also detect differential
expression of collagens XVIII and IVa3 expressed by the
poorly metastatic melanoma whereas laminin b2 and nidogen
1 were only detected in the ECM of metastatic melanoma
(Table III and supplemental Table S5).
Lysyl oxidases are enzymes capable of cross-linking colla-
gens and elastin (38). Both tumor types expressed lysyl oxi-
dase-like 1 (LOXL1) in the same proportions, whereas lysyl
oxidase-like 2 (LOXL2) was found to be expressed by the
A375 but not detected in the MA2 tumors. Conversely, LOXL3
and LOXL4 were not detected in A375 tumors but were pres-
ent in the MA2 tumors. Emilins are ECM proteins that bind
elastin and ECM fibrils (39). In our study, we observed that,
whereas both tumor types expressed Emilin 1, only the MA2,
highly metastatic tumors expressed also the two other related
proteins Emilin 2 and Emilin 3. Interestingly, elastin was found
in both tumor types but showed a 10-fold increase in the ECM
of MA2 as compared with that of A375 (Table III).
Most of the collagens were found in both tumor types in the
same proportions (collagens I, III, V), whereas some were
detected in only one of the two tumor types (collagens IV
chain a3, IX chain a1, XVIII in A375 tumors and collagens VI
chain a6, VIII chains a1 and a2, X, XIV, XXVII, XXVIII in MA2
tumors).
Although we do not yet fully understand the functional
significance of these examples, we report here for the first
time a detailed composition of melanoma extracellular matri-
ces, which can lead to further analyses.
Understanding the Origins of the Tumor Extracellular Ma-
trix—Another challenging question when studying the tumor
microenvironment is to understand the origin of the tumor
ECM; that is, whether the tumor ECM is produced and se-
creted by the tumor cells themselves, by the stromal cells or
by both compartments. To address this question, we pursued
the analysis of the melanoma xenografts described above, by
identifying for each protein its origin: is the protein secreted by
the human tumor cells or by the murine stroma? The murine
sequence of a given protein is, in most cases, sufficiently
different from its human ortholog to be distinguished by pro-
teomic analyses (supplemental Fig. S3). The mass spectro-
metric analysis allowed us to distinguish the human proteins
from their murine counterparts. The origin of a protein could
not be determined in only a very few cases (protein indicated
as “indistinguishable” in column D of supplemental Table S6
such as S100A10 in the A375 ECM or SRPX in the MA2
matrisome). In order to be able to identify without ambiguity
the origin of each protein, we required that proteins needed to
be detected in two independent samples with at least two
species-specific peptides in one of them. Using this strategy,
we identified for each tumor type a set of matrisome proteins
exclusively secreted by the (human) tumor cells, and another
set exclusively secreted by the (murine) stromal cells (Fig. 5
and supplemental Table S6). Extracellular matrix proteins and
proteases found in plasma, fibrinogen (Fg) subunits, plasmin-
ogen (Plg), thrombin (F2) and Factor XIIIa1, were all, in agree-
ment with their function, found to be expressed exclusively
from the mouse genome. In addition, we found proteins such
as fibrillin-1, fibronectin etc. that are secreted by both the
tumor cells and the stromal cells. Among these latter proteins
are several basement membrane components: collagen IV,
a1, a2, a3, a5 chains, collagen XVIII, perlecan (HSPG2), and
nidogen 1.
To analyze further the relative contributions of the two
cellular compartments to the secretion of a given protein, we
developed a semiquantitative measure. In brief, we calculated
the ratio of the observed precursor-ion MS intensities for
sequence-distinguishable homologous peptides from the
mouse versus human proteins (supplemental Fig. S3 and
supplemental Table S6). We consider a ratio above five to
indicate that the contribution of the tumor cells to the secre-
tion of the protein of interest is predominant (indicated in
orange in Fig. 5 and supplemental Table S6C). Conversely, a
ratio under 0.2 indicates a greater contribution from the
stroma (Fig. 5 and supplemental Table S6C, proteins high-
lighted in green). Finally, some proteins are secreted in sig-
nificant proportions by both compartments—ratio between
0.2 and 5 (Fig. 5 and supplemental Table S6C, proteins high-
lighted in yellow). We conclude from these data that both
tumor cells and stromal cells contribute, although differen-
tially, to the secretion of proteins making up the tumor ECM.
Our results are in agreement with recent data from the
literature. For example, periostin, a known ECM glycoprotein
involved in tumor progression and metastasis formation was
expressed exclusively by the stroma in A375 tumors, whereas
its expression was also induced in the tumor cells in MA2
tumors. This result conforms with a gene expression study by
Tilman et al. who showed that periostin is not expressed by
normal skin but becomes expressed by melanoma cells and
the stroma during tumor progression and metastasis forma-
tion (40). Conversely, the basement membrane components,
laminin chains a5 and c1, were only expressed by the tumor
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TABLE III
The tumor ECM changes with tumor’s metastatic potential. Color code represents the number of peptides and total peptide precursor ion
abundance of each protein in the two independent samples used to define the ECM compositions of non-metastatic (A375) and metastatic
(MA2) human melanoma xenografts. Values used to generate the table were extracted from columns I (number of unique peptides) and J
(peptide abundance) of supplemental Table S5B (A375) and supplemental Table S5D (MA2). Dash (—) indicates that the protein was not
detected in either sample from a given tissue. Proteins included in this table were found in two independent samples with at least two peptides
in one of the two samples. Uniprot accession numbers are given in supplemental Table S5
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cells in the A375 tumors and were secreted by both com-
partments (laminin c1 chain) or exclusively secreted by the
stroma (laminin a5 chain) in the MA2 tumor. Of interest,
laminin 511, composed of the a5, b1 and c1 chains has been
shown recently to promote melanoma cell migration and inva-
sion (41).
FIG. 5. The tumor extracellular ma-
trix is secreted by both tumor cells
and stromal cells and differs with met-
astatic potential. A, Proteins secreted
by A375 tumors and not by MA2 tumors.
B, Proteins secreted by MA2 tumors and
not by A375 tumors. C, Proteins ex-
pressed by both tumor types and by the
same compartment in the two tumor
types. D, Proteins expressed by both tu-
mor types but by different compart-
ments. Proteins are sorted by tumor type
and by their origins: tumor (red), stroma
(blue), or both (yellow: similar abundance
of the human and mouse proteins, or-
ange: human form is at least 5 times
more abundant than the mouse form,
green: the mouse form is at least 5 times
more abundant than the human form in
the two samples, ratios were calculated
using the values indicated in column Y
and values are given in column Z of
supplemental Table S6B and 6D) and by
category. UniProt accession numbers
are given in supplemental Table S6 (col-
umns D and E). The number of shared
peptides (common to human and mouse
sequences) and of human- and mouse-
specific peptides is given for each pro-
tein (data were extracted from columns
V and W of supplemental Table S6B
and 6D). BM indicates basement mem-
brane proteins, H indicates proteins in-
volved in hemostasis (i.e. plasma-de-
rived - as expected, all of these are
murine). Asterisks (*) indicate that, in ad-
dition to the identification of human- and
mouse-specific peptides, the entries had
a few peptides observed corresponding
to distinct isoforms involving point mu-
tations or exon deletions. For simplicity
the isoforms are combined here. For
detailed information, see Extended Ex-
perimental Procedure and supplemental
Table S6.
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FIG. 6. Hyaluronan and proteoglycan link protein-1 (HAPLN1) is overexpressed in metastatic melanoma and secreted by the tumor
cells. A, Numbers of nondistinguishing, species-specific and total peptides identified in the two metastatic tumor samples. In addition to
peptides common to both the human and murine proteins, two human-specific peptides and no murine-specific peptide were detected,
indicating that HAPLN1 is secreted by the tumor cells. Moreover, the two proteins are 96% identical in sequence so there are only a few
diagnostic peptides. B, Sequence alignment of human and murine HAPLN1. Peptides identified by LC-MS/MS are highlighted in yellow if the
peptide is identical in the two species and in pink if the peptide matches the human protein sequence. The identification of human-specific
peptides and not closely related mouse peptides suggests that HAPLN1 is secreted exclusively by the tumor cells. C, Alignment of the
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Our study is the first to report the detailed composition and
origin of the tumor extracellular matrix at the protein level and
highlights many proteins of potential importance for meta-
static disease. Therefore, we conclude that the matrisome
components secreted by the tumor cells vary with the meta-
static potential of the tumor cells. In addition, the matrisome
components secreted by the stromal cells also change in
response to the metastatic potential of the tumor cells, indi-
cating significant cross-talk between the tumor cells and the
stromal cells.
Hyaluronan and Proteoglycan Link Protein-1 (HAPLN1) is
Overexpressed in Metastatic Melanoma and is Secreted Ex-
clusively by the Tumor Cells—To illustrate the potential of this
approach, we considered the example of hyaluronan and
proteoglycan link protein-1 (HAPLN1), which was found to be
expressed exclusively in the metastatic tumors and specifi-
cally secreted by the tumor cells (Table III, Fig. 5, and
supplemental Table S5B). The function of HAPLN1 is to link
proteoglycans to hyaluronic acid thus participating in the
architecture of the extracellular matrix (42). Interestingly, this
gene was previously found to be up-regulated in gene expres-
sion arrays comparing MA2 tumors to A375 tumors (43) and is
often up-regulated in highly metastatic cell lines or human
tumors (44, 45).
Additionally, the Human Protein Atlas database indicates an
increased expression of HAPLN1 in malignant melanoma (http://
www.proteinatlas.org/ENSG00000145681/cancer/malignant
melanoma) (46).
Our proteomic analysis identified the origin of HAPLN1 as
being secreted by the tumor cells and not by the stromal cells,
since human-specific but not murine-specific peptides were
detected (Figs. 6A, 6B and supplemental Table S6B). We
confirmed the expression of HAPLN1 in metastatic and not in
nonmetastatic tumors by immunohistochemistry (Fig. 6D).
The fragment used to generate the antibody is 89% identical
with the corresponding murine sequence (Fig. 6C), which
renders ambiguous the identification of the origin of HAPLN1
by immunohistochemistry alone. This example demonstrates
that our proteomics strategy is a method of choice to identify
without ambiguity the origin of a given protein of tumor ECM.
DISCUSSION
We report here the development of proteomic methods to
characterize in detail the biochemical composition of the ex-
tracellular matrix from normal and tumor tissues. In addition to
the development of this experimental strategy it was essential
to develop a systematic and objective bioinformatic definition
of those proteins that should be considered as part of, or
associated with, the ECM—we call this set of proteins the
“matrisome” (Fig. 7). This detailed inventory of ECM and
ECM-associated proteins serves as a basis for analyses of the
tissue specificity of ECM composition and of changes that
occur during physiological or pathological processes, exem-
plified here by analyses of cancer. These methods can now be
applied to diverse biological questions concerning ECM biol-
ogy and pathology and we present here detailed protocols to
allow their exploitation by others.
In Silico Definition of the Matrisome—Taking advantage
of the characteristic domain-based organization of ECM pro-
teins, we established a bioinformatic pipeline aimed at iden-
tifying all ECM proteins encoded within the genome, based on
the presence and absence of diagnostic domains. In parallel
with the definition of this “core” group of extracellular com-
ponents (structural and fibrillar glycoproteins and proteogly-
cans), we also defined, using similar methodology, an inclu-
sive list of matrisome-associated proteins, comprising 1)
ECM-affiliated proteins (affiliated either structurally or physi-
cally with the core matrisome), 2) ECM-remodeling enzymes
and iii) secreted factors such as growth factors and cytokines,
known or suspected to bind to ECM. In addition to providing
an atlas of the matrisome, these lists were incorporated into
the proteomic pipeline to annotate automatically the mass
spectrometric output (see below and Fig. 7).
The compilation of matrisome-diagnostic domains and our
inventory of 1056 matrisome genes in the human genome
(accounting for 4% of the proteome), including 278 core ma-
trisome genes (1% of the proteome) represents the most
comprehensive definition of extracellular matrix components
to date and provides a framework for future analyses of the
ECM of normal and diseased tissues. Indeed, the list of core
matrisome proteins should serve as a more comprehensive
alternative to GO annotation of ECM proteins, which is inad-
equate in several ways. This list of 278 core matrisome pro-
teins includes all previously known ECM proteins as well as a
number of previously unknown proteins (see supplemental
Table S3). Of note, this systematic approach would not allow
the identification of proteins that lack ECM-diagnostic do-
mains and that are not known to be part of the extracellular
matrix. However, the domain and protein lists are intended to
evolve as the in vivo characterization of the extracellular ma-
trix progresses and knowledge in the field advances; one
could readily add to the bioinformatic pipeline new domains or
criteria, thereby including additional proteins in the lists. It is
worth noting that all proteins detected by the mass spectrom-
etry but not included in the lists of bioinformatically defined
matrisome proteins are included in the supplemental Tables
and available for search by additional bioinformatic analyses.
sequence of the human protein fragment (amino acids 16 to 75) used to generate the anti-HAPLN1 antibody with the murine protein sequence
(amino acids 16 to 77), which is 89% identical. D, HAPLN1 is up-regulated in MA2 tumors. Immunohistochemistry using anti-HAPLN1 antibody
of A375 (upper panel) and MA2 (lower panel) tumor sections. Left panels show HAPLN1 staining, middle panel DAPI staining of the nuclei and
right panels merge images.
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The Composition of Extracellular Matrices In Vivo—To study
the global composition of the extracellular matrix from tissues
and tumors, we employed a protocol originally designed to
extract proteins from several intracellular and membranous
subcellular compartments. This protocol largely depletes in-
tracellular proteins and in turn enriches for insoluble ECM and
ECM-associated proteins. Hence, this strategy focuses on the
insoluble components present in the ECM and proteins tightly
associated with these components. The enrichment for ECM
components was confirmed by the mass spectrometric anal-
ysis of the composition of protein extracts. It is important to
note that this protocol will miss proteins loosely bound to the
ECM and eluted by the sequential extractions. However, such
proteins would be detectable in the extracted fractions using
targeted proteomics (see below).
Our analyses of the lung and colon showed that the ECM of
a given tissue comprises between 100 and 200 proteins,
including a set of tissue-specific proteins that represent 10%
to 30% of the total. Considering both the lung and colon
together, we detected 67 of the 195 murine ECM glycopro-
teins predicted bioinformatically (representing a third of the
predicted ECM glycoproteins), 30 of the 43 collagen subunits
and eight of the 36 proteoglycans encoded by the murine
genome. We suspect that those matrisome proteins not de-
tected will be found in other tissue types or at different de-
velopmental stages; for example, some proteoglycans, such
as aggrecan or fibromodulin, and some collagens (collagen II
and collagen IX) are known to be cartilage-specific (33, 47)
and many ECM proteins appear to be selectively or exclu-
sively expressed in the nervous system (48). Thus, our cou-
pled mass spectrometric and bioinformatic approaches have
allowed a more extensive characterization of the ECM of
tissues than has been possible previously.
The proportions of the predicted ECM-associated protein
categories found in our experimental samples are significantly
lower, and most of them were only detected after peptide sep-
aration by isoelectric focusing. ECM modification enzymes and
secreted growth factors are expected to be present at lower
molar ratios than structural proteins and therefore to be less well
represented in the data sets. Greater solubility (looser binding to
ECM) might also explain in part the fact that fewer are detected
in our data sets to date. Finally, the list of ECM-affiliated proteins
may well be somewhat inflated, since we included in our lists
entire families of proteins if any members of the family were
identified in any of our experimental samples (examples include
annexins, galectins, mucins, etc.), and this will increase the
probability that individual proteinsmay not be found in particular
samples. The purpose was to avoid ignoring potential matri-
some components but this inclusive nature of the ECM-asso-
ciated category inevitably increases the probability that such
proteins will not be found in particular samples. Some of these
proteins may indeed not be ECM-associated.
We anticipate that further analyses will allow detection of
specific subsets of proteins present at lower levels in the
ECM-enriched fractions. Targeted proteomic methods (such
as Accurate Inclusion Mass Screening or Multiple Reaction
FIG. 7. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices.We
propose here to update and broaden the use of the term “matrisome”—first used by Martin and collaborators in 1984 to define supramolecular
basement membrane complex (including collagen IV, laminin, nidogen, and proteoglycan) (57)—to define the universe of ECM proteins and
their complexes that can contribute to ECM structures. The domain-based bioinformatic analyses defined a set of extracellular matrix proteins
(core matrisome) and an additional set of matrisome-associated proteins within the human and mouse genomes. This in silico definition of the
matrisome was further used to annotate the proteomic output. The combination of a robust definition of matrisomal proteins and a high
throughput proteomics pipeline led to the identification of more than 100 extracellular matrix proteins within any given tissue or tumor.
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Monitoring, etc.) are designed to detect specific peptides in
samples and are particularly useful to detect low-abundance
proteins within a complex mixture (49–51). Using as re-
sources the in silico and experimentally determined matri-
somes reported here, one can now select for each matrisome
protein, signature peptides particularly likely to be detected
by MS (49, 52) and use this peptide list for enhanced detec-
tion of lower abundance proteins of interest. Such ap-
proaches based on our lists of candidate proteins will, no
doubt, allow the identification of more low-abundance pro-
teins such as growth factors. Similar methods could also be
used to detect alterations in solubility of particular proteins by
analysis of the extracted fractions.
Identifying the Origin of the Tumor Extracellular Matrix—
Recent research in cancer biology has demonstrated that
tumor cells not only need to accumulate genetic alterations
allowing them to proliferate but need also to be surrounded by
a locally permissive microenvironment, which markedly af-
fects tumor progression (53, 54). In this context, the surround-
ing stroma, including the tumor extracellular matrix, is of great
interest. Previous proteomic analyses of tumors have not
focused on the ECM, although ECM proteins were detected
among the tumor proteins analyzed (55, 56).
We demonstrate here that our methodology can be applied
to characterize specifically and in detail the ECM of tumors.
Moreover, mass spectrometry is a method of choice to dis-
tinguish human from murine protein sequences and thus can
address the question of the tumor or stromal origins of tumor
extracellular matrix in human into mouse xenograft systems.
Our data prove that the origin of the tumor extracellular matrix
is dual and comes from both the tumor cells and the stromal
cells, as might well have been expected. However, our anal-
yses provide semi-quantitative estimates of the origins (tumor
cell or stromal cell) for over a hundred ECM proteins, which
has not been feasible before. Furthermore, we show that the
matrisome components secreted by the tumor cells vary sig-
nificantly with the metastatic potential of the tumor cells.
Moreover, the matrisome components secreted by the stro-
mal cells also change in response to the metastatic potential
of the tumor cells, indicating significant cross-talk between
the tumor cells and the stromal cells. This study is the first to
report the detailed composition and origin of the tumor extra-
cellular matrix at the protein level. It will be of interest to
investigate the significance of these changes for tumor
progression.
In conclusion, the strategy presented offers a new perspec-
tive to the analysis of the extracellular matrix. Moreover, the
methods described here can reveal the presence and origins
of novel or unsuspected proteins within the ECM and, thus,
novel molecular mechanisms by which the ECM could influ-
ence cancer progression and metastasis formation. In addi-
tion to revealing novel molecular players whose functional
contributions can then be investigated, this approach has the
potential to identify biomarkers that can serve as prognostic
and diagnostic tools. The methods described here are gen-
eralizable and portable and similar strategies could readily be
applied to many other physiological (e.g. development, angio-
genesis) and pathological (e.g. fibrosis, wound healing, ge-
netic disease) processes that involve important changes in
ECM.
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